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Abstract Primary Sjo¨gren’s syndrome (pSS) can be
complicated by distal renal tubular acidosis (dRTA), which
may contribute to low bone mineral density (BMD). Our
objective was to evaluate BMD in pSS patients with and
without dRTA as compared with healthy controls. BMD of
lumbar spine (LS) and femoral neck (FN) was measured in
54 pSS patients and 162 healthy age- and sex-matched
controls by dual-energy X-ray absorptiometry (DXA).
dRTA was defined as inability to reach urinary pH\5.3 after
an ammonium chloride (NH4Cl) test. LS- and FN-BMD were
significantly higher in pSS patients compared with controls
(1.18 ± 0.21 g/cm2 for patients vs. 1.10 ± 0.18 g/cm2 for
controls, P = 0.008 and 0.9 ± 0.16 g/cm2 for patients vs.
0.85 ± 0.13 g/cm2 for controls, P = 0.009, respectively).
After adjustment for BMI and smoking, the LS- and FN-
BMD remained significantly higher. Patients with dRTA
(N = 15) did not have a significantly different LS- and FN-
BMD compared with those without dRTA (N = 39) after
adjustment for BMI, age, and gender. Thirty-seven (69 %)
pSS patients were using hydroxychloroquine (HCQ).
Unexpectedly, pSS patients had a significantly higher LS-
and FN-BMD compared with healthy controls. Patients with
dRTA had similar BMD compared with patients without
dRTA. We postulate that an explanation for the higher BMD
in pSS patients may be the frequent use of HCQ.
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Introduction
Sjo¨gren syndrome (SS) is a prevalent chronic autoimmune
disease characterized by impairment of exocrine glands
and systemic manifestations, affecting between 1 and 3 %
of the general population [1]. SS can be present alone
(primary Sjo¨gren syndrome (pSS)) or accompanied by
other autoimmune diseases such as systemic lupus ery-
thematosus (SLE) or rheumatoid arthritis (RA) and is then
called secondary Sjo¨gren syndrome (sSS) [2, 3]. The
classical symptoms of SS include dryness of mouth (xe-
rostomia), dryness of eyes (xerophthalmia) and less com-
monly dryness of pharynx, larynx, and/or vagina [4].
Extraglandular manifestations can be divided into general
symptoms (e.g., fatigue, arthralgia, and myalgia) and in
systemic manifestations [5]. Common systemic manifes-
tations include renal tubular acidosis, non-erosive sym-
metrical arthritis, interstitial lung disease, peripheral
polyneuropathy, autoimmune thyroiditis, and B cell lym-
phoma [6–11].
Distal renal tubular acidosis (dRTA) is one of the less
well recognized complications. Recently, we reported a
considerably high prevalence of dRTA in pSS [7]. dRTA is
characterized by the inability of patients to lower urinary
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pH\5.3 due to a defect in the proton secreting machinery
of the alpha-intercalated cells in the collecting ducts of the
kidney [12]. Patients with dRTA have a non-anion gap
metabolic acidosis with urinary pH C5.3.
The association between chronic metabolic acidosis and
alteration in bone cell function has been demonstrated both
in vitro and in vivo [13, 14]. During metabolic acidosis,
there appears to be an exchange of protons for calcium ions
in bone mineral to buffer the excess of protons [13]. The
metabolic effects of dRTA in pSS remain conflicting.
Several case-series have shown a low bone mineral density
(BMD) in patients with dRTA in pSS [15, 16]. Some recent
studies report an increased prevalence of low BMD in
patients with dRTA [17, 18], while other studies did not
report a significant difference in patients with dRTA [19,
20]. Epidemiologic data on BMD in SS are lacking.
We hypothesized that BMD is significantly decreased in
patients with pSS and especially in those with dRTA.
Therefore, our aim was to evaluate BMD in pSS patients
with and without dRTA as compared with healthy controls.
Methods
Study Cohort
Patients were selected from the outpatient clinic of the
department of internal medicine (division of clinical
immunology) of Erasmus MC in Rotterdam, The Nether-
lands. pSS was defined according to the Revised American-
European classification criteria [21]. The results of salivary
gland biopsy were retrieved when available. Additional
inclusion criteria for this study included age[18 years and
an estimated glomerular filtration rate [30 ml/min. The
exclusion criteria were other underlying autoimmune dis-
eases, known risk factors for osteoporosis (vitamin D level
\20 nmol/l, untreated hyperthyroidism, hyperparathy-
roidism, use of corticosteroids (prednisone equivalent of
[7.5 mg for[3 months in the last year), use of bisphos-
phonates, multiple myeloma, mastocytosis). All partici-
pants were asked about menopausal status (if applicable),
current smoking and history of fractures, and use of med-
ication (Table 1). Data from BMD in the healthy control
group were obtained from the ERF (Erasmus Rucphen
Family) study database [22]. The matching criteria for the
controls were age and sex. For every pSS patient, three
controls were selected.
Bone Mineral Density
In all subjects, we measured BMD of the lumbar spine (L2-
L4) and femoral neck using a dual-energy X-ray absorp-
tiometry (DXA) scanner (Prodigy Pro Full P8, enCORETM
Software Platform, GE Medical Systems Lunar, Belgium).
Scans were performed according to the manufacturer’s
guidelines and analyzed according to ISCD rules [23]. The
healthy control group was scanned with a different DXA
device from the same type (GE Lunar Prodigy device, GE
Healthcare, USA) [24]. As described by Enneman et al., a
cross-calibration was performed using a spine phantom
which showed that the measurements of the new scanner
(the one we used for the patients in the current study) were
slightly higher by a factor 1.0101 [24]. Therefore, we
divided our results by this factor for comparison with the
data from the ERF study. BMD was expressed in grams per
square centimeters.
Biochemical Parameters
In all patients, we measured vitamin D status. Anti-nuclear
antibodies (ANA), SSA/Ro52, SSA/Ro60, SSB/La auto-
antibodies, and rheumatoid factor (RF) were also measured
in all patients using previously reported methods [25].
Serum was collected before 10:00 a.m. and analyzed the
same day. Patients were not instructed to be fasting. The
following bone turnover markers (BTMs) were measured
in patients: serum N-terminal propeptide of type I procol-
lagen (PINP) and serum bone-specific alkaline phosphatase
(BAP, both as measures of bone formation) and serum
N-terminal crosslinking telopeptide of type I collagen
(NTX, as measure for bone resorption). There were no data
available on BTMs in the healthy control group.
Distal Renal Tubular Acidosis
dRTA was defined as an abnormal NH4CL test and the
absence of any other known causes for dRTA (e.g., med-
ication, hypercalciuria) [12]. The NH4CL test is defined as
abnormal if patients fail to achieve a urinary pH \5.3
within 4 h after intake of ammonium chloride (1 ml/kg
body weight) [26].
Statistics
All results are expressed as means with standard deviations.
Comparisons of the normally distributed continuous vari-
ables between two groups were performed using the student
T test. Since BTMs were not normally distributed, we com-
pared BTMs between the two groups using the Mann–
Whitney U test. Linear regression analysis was used to
estimate the effect of having pSS on BMD before and after
adjustment for body mass index (BMI) and smoking. Linear
regression analysis was used to estimate the effect of having
dRTA on BMD before and after adjustment for BMI, age,
and gender. A P value\0.05 was considered significant. All
analyses were performed in SPSS (version 21, IBM).
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Results
Study Cohort and Baseline Characteristics
The study cohort included 54 patients with pSS and the
control group consisted of 162 subjects. Initially, 62
patients participated in the study. Eight patients were
excluded, including four patients who were unable to
complete the NH4CL test due to repeated vomiting, one
patient in whom the DXA-scan was not reliable due to
scoliosis and three patients were using bisphosphonates.
No patients were excluded because of long-term use of
corticosteroids and only three patients were using low dose
corticosteroids for a medical condition other than pSS. The
baseline characteristics of the study cohort are shown in
(Table 1). Similar to previous studies on pSS, our cohort
has a female:male ratio of approximately 10:1 [27]. Thirty-
seven (69 %) patients with pSS were using HCQ. In
addition to medication for pSS, other commonly used drugs
in this cohort were vitamin D with calcium supplements
(N = 11). None of these patients reported a fracture in their
medical history.
Table 1 Characteristics of the study cohort
Study cohort (N = 54) No dRTA (N = 39) dRTA (N = 15) Control group (N = 162)
Demographics
Age, years ± SD 57.3 ± 10.6 60.1 ± 9.4 50.2 ± 10.5 57.3 ± 10.6
Female gender, n (%) 50 (93) 36 (92) 14 (93) 150 (93)
Body mass index, kg/m2 ± SD 26.8 ± 6.2 26.9 ± 6.2 26.6 ± 6.6 27.3 ± 5.3
Current smokers, n (%) 2 (4) 0 (0) 2 (13) 60 (37)
Postmenopausal, n (%) 36/50 (72) 5/36 (14) 5/14 (36) 119 (69)
Age at menopause, years ± SD 47.4 ± 6.1 47.0 ± 6.5 48.4 ± 4.9 47.9 ± 6.1
Previous fractures, n (%)§ 19 (35) 11 (28) 8 (53) n.a
Disease duration, years ± SD 12.1 ± 7.2 12.2 ± 8.0 11.5 ± 5.6 –
Biochemical
Serum 25-OH-Vitamin D, nmol/L ± SD 70.4 ± 21,8 69.7 ± 22.1 72.5 ± 21.7
Serum intact PTH, pmol/L ± SD 4.3 ± 1.5 4.5 ± 1.5 3.7 ± 1.5
Serum calcium, mmol/L ± SD 2.39 ± 0.08 2.39 ± 0.07 2.38 ± 0.16
Serum phosphate, mmol/L ± SD 1.09 ± 0.15 1.10 ± 0.14 1.06 ± 0.16
Serum creatinine, lmol/L ± SD 76.8 ± 18.6 72.9 ± 11.8 86.7 ± 27.9
Serum PINP, lg/L ± SD 38.6 ± 18.5 41 ± 19.2 32.5 ± 15.4
Serum BAP, lg/L ± SD 14.2 ± 4.1 14.7 ± 4.3 12.8 ± 3.3
Serum NTX, nM BCE ± SD 17.2 ± 4.4 17.3 ± 4.6 16.8 ± 3.8
Immunology
Anti-nuclear antibodies, n (%) 41 (76) 28 (72) 13 (87)
Rheumatoid factor, n (%) 32/42 (76) 21/29 (72) 11/13 (85)
SSA/Ro52, n (%) 42 (78) 29 (74) 13 (87)
SSA/Ro60, n (%) 40 (74) 26 (67) 14 (93)
SSB/La, n (%) 31 (57) 18 (46) 13 (87)
Positive salivary gland biopsy, n (%)} 23/27 (85) 14/18 (78) 9/9 (100)
Medication
Hydroxychloroquine, n (%) 35 (69) 23 (59) 12 (80)
Vitamin D supplements, n (%) 11 (20) 9 (23) 2 (13)
Glucocorticoids, n (%) 3 (6) 2 (5) 1 (7)
Other immunosuppressive drugs, n (%) 4 (7) 2 (5) 2 (13)
Data are presented as mean ± standard deviation (SD) and no. (%)
} Salivary gland biopsies were performed in 34/54 patients, but a focus score could be retrieved for only 27 patients; Rheumatoid factor was
measured in 42/54 patients
 Other immunosuppressive therapy consisted of azathioprine, colchicine, or methotrexate
§ Data about previous fractures could not accurately be retrieved
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BMD of pSS Patients Compared with Healthy
Controls
BMD of fifty-four pSS patients was compared with the age-
and sex-matched control group of 162 subjects. The LS-
and FN-BMD were significantly higher in the pSS patients
compared with the healthy control group (1.18 ± 0.21 g/
cm2 for pSS patients vs. 1.10 ± 0.18 g/cm2 for the control
group, P = 0.008 and 0.9 ± 0.16 g/cm2 for pSS patients
vs. 0.85 ± 0.13 g/cm2 for the control group, P = 0.009,
respectively) (Fig. 1).
After adjustment for BMI and smoking, the LS- and FN-
BMD remained significantly higher (b = 0.10 ± 0.030 g/
cm2, P\ 0.001 and b = 0.077 ± 0.022 g/cm2, P\ 0.001)
(Table 2).
The Effect of Distal Renal Tubular Acidosis on BMD
Fifteen pSS patients had an urinary acidification defect as
measured by the NH4CL test. Between both groups the
levels of biochemical parameters and the use of medication
were similar (Table 1). Patients with dRTA were signifi-
cantly younger compared with those without dRTA
(Table 1). Both the LS- and FN-BMD were significantly
higher in patients with an urinary acidification defect
compared with those without an urinary acidification defect
(LS: 1.29 ± 0.16 g/cm2 vs. 1.14 ± 0.21 g/cm2, P = 0.018
and FN: 1.0 ± 0.19 g/cm2 vs. 0.87 ± 0.14 g/cm2,
P = 0.007). After adjustment for BMI, age, and gender,
both the LS- and FN-BMD were not significantly higher
anymore (LS: b = 0.12 ± 0.064 g/cm2, P = 0.065 and
FN: b = 0.07 ± 0.049 g/cm2, P = 0.16) (Table 3).
Bone mineral density
LS-BMD FN-BMD
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Patients
Controls
P = 0.008 P = 0.009
g/
cm
2
Fig. 1 Comparison of BMD between patients and controls. The
graph shows the bone mineral density of the lumbar spine and the
femoral neck of patients with primary Sjo¨gren syndrome (N = 54)
compared with healthy age- and sex-matched controls (N = 162). SD
standard deviation, BMD bone mineral density, LS-BMD bone
mineral density of the lumbar spine, FN-BMD bone mineral density
of the femoral neck
Table 2 Multiple regression
analysis of factors related to LS-
and FN-BMD between patients
(N = 54) versus controls
(N = 162)
Variable LS-BMD FN-BMD
B Std. error b B Std. error b
(Constant) 0.797 0.063 0.587 0.047
pSS 0.103 0.030 0.237** 0.077 0.022 0.235**
BMI 0.010 0.002 0.298** 0.009 0.002 0.350**
Smoking 0.061 0.029 0.147* 0.045 0.021 0.143*
Std. error standard error of the mean, pSS primary Sjo¨gren syndrome, BMI body mass index, LS-BMD bone
mineral density of the lumbar spine, FN-BMD, bone mineral density of the femoral neck
* P 0.01\ 0.05
** P\ 0.01
Table 3 Multiple regression
analysis of factors related to LS-
and FN-BMD between patients
with dRTA (N = 15) versus
patients without dRTA
(N = 39)
Variable LS-BMD FN-BMD
B Std. error b B Std. error b
(Constant) 1.292 0.217 1.175 0.166
dRTA 0.121 0.064 0.264 0.070 0.049 0.184
BMI 0.007 0.004 0.220 0.003 0.003 0.113
Gender -0.177 0.100 -0.226 -0.008 0.076 -0.012
Age -0.003 0.003 -0.157 -0.006 0.002 -0.405*
Std. error standard error of the mean, dRTA distal renal tubular acidosis, BMI body mass index, LS-BMD
bone mineral density of the lumbar spine, FN-BMD, bone mineral density of the femoral neck
* P\ 0.01
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Bone Turnover Markers in pSS Patients
In patients with dRTA serum, PINP was not significantly
higher compared with patients without dRTA (P = 0.093).
The other marker for bone formation, BAP, was also not
significantly different between both groups (P = 0.11).
The bone resorption marker NTX was not significantly
different between patients with and without dRTA
(P = 0.92) (data not shown).
Discussion
In the present study, we found that, contrary to expected,
pSS patients have significantly higher BMD than healthy
age- and sex-matched controls. We searched the available
literature but did not find another study reporting BMD
measurements in pSS patients as compared with a healthy
control group. Studies concerning BMD in autoimmune
diseases are mainly performed in lupus patients. In agree-
ment with Arampatzis et al. and Pongchaiyakul et al., we
found that patients with an urinary acidification defect did
not have a significantly different LS- and FN-BMD com-
pared with those patients without an urinary acidification
defect [19, 20].
Bushinsky et al. reported a decreased bone mineraliza-
tion in an acidotic environment in both in vitro and in vivo
studies [13, 14]. This makes us wonder what the reason is
that we did not find a lower BMD in patients with dRTA.
We hypothesize that the observed BMD in pSS patients
may be related to the use of hydroxychloroquine (HCQ)
which the majority (69 %) of patients in our study was
using. In case of systemic manifestations, therapy with
non-steroidal anti-inflammatory drugs or HCQ is advised.
HCQ has proven to be effective against fatigue, arthralgia,
and myalgia [28, 29]. Lakshminarayanan et al. and Mok
et al. reported that in lupus the use of HCQ was associated
with increased BMD of the hip [30, 31]. In both studies,
disease activity and use of corticosteroids were not sig-
nificantly different between both groups. Additionally, Xiu
et al. recently reported a reduced osteoclastogenesis by
TRAF3 degradation due to the effects of chloroquine in
mice, which may suggest that HCQ has direct effects on
bone metabolism [32]. Based on these clinical and bio-
chemical studies, we hypothesize that HCQ may have
beneficial effects on BMD.
In our cohort, it is unknown how long these patients
were treated with HCQ. We also did not have information
about past use of HCQ in patients, who are not using it
currently. Therefore, analyzing a possible association
between HCQ use and BMD would not be reliable in our
cohort. To demonstrate whether the use of HCQ has
beneficial effects on human bone cells, in vitro studies
should be performed.
We analyzed whether patients with dRTA also had
different BTM measurements compared with patients
without an urinary acidification defect. Since patients with
dRTA had similar LS- and FN-BMD compared with those
without dRTA, we expected that the BTMs measurements
would not be significantly different between both groups.
Indeed, all three BTMs (PINP, NTX, and BAP) were not
significantly different between patients with and without an
urinary acidification defect. Unfortunately, we could not
compare BTM measurements between pSS patients and the
healthy control group since data about BTM measurements
in the healthy controls is lacking.
The strength of this study is that we have reported new
data about the BMD values in a large cohort of pSS
patients. In addition, we analyzed the effects of dRTA, a
common complication of pSS, on BMD in pSS patients. A
limitation of this study is that we used a different DXA
scanner compared to Zillikens et al. although the type of
machine was the same and calibration was performed with
a spine phantom, making this an unlikely explanation for
our findings [22].
In conclusion, we found that both the LS- and FN-BMD
were higher in patients with pSS than in age and sex-matched
healthy controls. In addition, LS- and FN-BMD in patients
with an urinary acidification defect is comparable with
patients without an urinary acidification defect. An expla-
nation for the high BMD in pSS patients may be the frequent
use of HCQ, but future studies will have to confirm whether
indeed use of HCQ is associated with higher BMD.
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